Lidocaine for Status Epilepticus in Pediatrics

Canadian Journal of Neurological Sciences

Volumn 42, Issue 6, 2015, Pages 414-426

  Zeiler, Frederick A ^a   Zeiler, Kaitlin J ^b   Teitelbaum, Jeanne ^c   Gillman, Lawrence M ^a   West, Michael ^a   Kazina, Colin J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Misericordia Health Center   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

clinical pharmacology; epilepsy; epilepsy pediatric; neurocritical care; neurology neonatal; neurology pediatric; pediatric neurology; pediatrics; seizures; status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; LIDOCAINE; PHENYTOIN;

ARTICLE; BRADYCARDIA; CHILD; CONTINUOUS INFUSION; DATA BASE; DISEASE CONTROL; DISEASE REGISTRY; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EPILEPTIC STATE; HUMAN; HYPOTENSION; METABOLIC ACIDOSIS; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TACHYCARDIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; PROSPECTIVE STUDY; SEIZURES; STATUS EPILEPTICUS;

ANTICONVULSANTS; HUMANS; LIDOCAINE; PEDIATRICS; PHENYTOIN; PROSPECTIVE STUDIES; SEIZURES; STATUS EPILEPTICUS;

EID: 84949234397     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2015.278     Document Type: Article

References (45)

1. Bath KG, Scharfman HE. Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research. Epilepsy Behav. 2013;26: 427-39.
2. Zhang LL, Zeng LN, Li YP. Side effects of phenobarbital in epilepsy: A systematic review. Epileptic Disord. 2011;13:349-65.
3. Ikonomidou C, Turski L. Antiepileptic drugs and brain development. Epilepsy Res. 2010;88:11-22.
4. Vento M, de Vries LS, Alberola A, Blennow M, Steggerda S, Greisen G, et al. Approach to seizures in the neonatal period: A European perspective. Acta Paediatr. 2010;99:497-501.
5. Sánchez Fernández I, Abend NS, Agadi S, An S, Arya R, Carpenter JL, et al. Gaps and opportunities in refractory status epilepticus research in children: A multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG). Seizure. 2014; 23:87-97.
6. Capovilla G, Beccaria F, Beghi E, Minicucci F, Sartori S, Vecchi M. Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League Against Epilepsy. Epilepsia. 2013;54(Suppl 7):23-34.
7. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3-23.
8. Ottosson JO. Effect of lidocaine and procaine on the electroshock seizure threshold, with a comparison of the effects of phenytoin and phenobarbital. Acta Psychiatr Scand Suppl. 1960;35(145): 33-48.
9. Borowicz KK, Banach M. Antiarrhythmic drugs and epilepsy. Pharmacol Rep. 2014 Aug;66(4):545-51.
10. Cervenka MC, Hartman AL, Venkatesan A, Geocadin RG, Kossoff EH. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. Neurocrit Care. 2011;15:519-24.
11. De Giorgio CM, Altman K, Hamilton-Byrd E, Rabinowicz AL. Lidocaine in refractory status epilepticus: confirmation of efficacy with continuous EEG monitory. Epilepsia. 1992;33:913-6.
12. Yang YC, Huang CS, Kuo CC. Lidocaine, Carbamazepine, and Imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na channels. Anesthesiology. 2010;113:160-74.
13. Kuo C-C. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na channels. Mol Pharmacol. 1998;54:712-21.
14. Kuo C-C, Lou B-S, Huang R-C. Inhibition of Na( + ) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol. 2000;57:135-43.
15. Aggarwal P, Wali JP. Lidocaine in refractory status epilepticus: A forgotten drug in the emergency department. Am J Emerg Med. 1993;11:243-4.
16. Bernhard CG, Bohm E, Hojeberg S. A new treatment for status epilepticus. AMA Arch Neurol Psychiatry. 1955;74:208-14.
17. Boylan GB, Rennie JM, Chorley G, Pressler RM, Fox GF, et al. Second-line anticonvulsant treatment of neonatal seizures: A video-EEG monitoring study. Neurology. 2004;62:486-8.
18. Dan B, Boyd SG. Stimulus-sensitive burst-spiking in burstsuppression in children: implications for management of refractory status epilepticus. Epileptic Disord. 2006;8:143-50.
19. Fallah R, Gofrani M. Comparison of intravenous lidocaine and midazolam infusion for refractory status epilepticus in children. J Ped Neurol. 2007;5:287-90.
20. Hamano S, Sugiyama N, Yamashita S, Tanaka M, Hayakawa M, Minamitani M, et al. Intravenous lidocaine for status epilepticus during childhood. Dev Med Child Neurol. 2006;48:220-2.
21. Hellström-Westas L, Westgren U, Rosén I, Svenningsen NW. Lidocaine for treatment of severe seizures in newborn infants. I. Clinical effects and cerebral electrical activity monitoring. Acta Paediatr Scand. 1988;77:79-84.
22. Hellström-Westas L, Svenningsen NW, Westgren U, Rosén I, Lagerström PO. Lidocaine for treatment of severe seizures in newborn infants. II. Blood concentrations of lidocaine and metabolites during intravenous infusion. Acta Paediatr. 1992; 81:35-9.
23. Kobayashi K, Ito M, Miyajima T, Fujii T, Okuno T. Successful management of intractable epilepsy with intravenous lidocain and lidocain tapes. Pediatr Neurol. 1999;21:476-80.
24. Kwon SH, Seo HE, Hwang SK. The effectiveness and tolerability of adjunctive treatment with lidocaine in children with refractory status epilepticus. J Neurol. 2013;260(Suppl 1):S1-280.
25. Lago P, Boniver C, Casara GL, Laverda AM, Fiore A, Salvadori S, et al. Neonatal tuberous sclerosis presenting with intractable seizures. Brain Dev. 1994;16:257-9.
26. Lin JJ, Lin KL, Wang HS, Hsia SH, Wu CT. Effect of topiramate, in combination with lidocaine, and phenobarbital, in acute encephalitis with refractory repetitive partial seizures. Brain Dev. 2009;31:605-11.
27. Lin J, Lin K, Wang H. High dose lidocaine in the treatment of acute encephalitis with repetitive partial seizures in children. Epilepsia. 2007;48:154.
28. Lundqvist M, Agren J, Hellström-Westas L, Flink R, Wickström R. Efficacy and safety of lidocaine for treatment of neonatal seizures. Acta Paediatr. 2013;102:863-7.
29. MalingréMM, Van Rooij LG, Rademaker CM, Toet MC, Ververs TF, van Kesteren C, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr. 2006;165: 598-604.
30. Okumura A, Komatsu M, Abe S, Kitamura T, Matsui K, Ikeno M, et al. Amplitude-integrated electroencephalography in patients with acute encephalopathy with refractory, repetitive partial seizures. Brain Dev. 2011;33:77-82.
31. Rey E, Radvayani-Bouvet MF, Bodiou C, Richard MO, Torricelli A, Walti H, et al. Intravenous lidocaine in the treatment of convulsions in the neonatal period: monitoring plasma levels. Ther Drug Monit. 1990;12:316-20.
32. Shany E, Benzaqen O, Watemberg N. Comparison of continuous drip of midazolam or lidocaine in the treatment of intractable neonatal seizures. J Child Neurol. 2007;22:255-9.
33. Wakamoto H, Takahashi Y, Ebihara T, Okamoto K, Hayashi M, Ichiyama T, et al. An immunologic case study of acute encephalitis with refractory, repetitive partial seizures. Brain Dev. 2012;34:763-7.
34. Wallin A, Nergardh A, Hynning PA. Lidocaine treatment of neonatal convulsions, a therapeutic dilemma. Eur J Clin Pharmacol. 1989;36:583-6.
35. Yamamoto H, Aihara M, Niijima S, Yamanouchi H. Treatments with midazolam and lidocaine for status epilepticus in neonates. Brain Dev. 2007;29:559-64.
36. Higgins JPT, Green S. eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0. Available at: http:handbook. cochrane.org.
37. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analysis: The PRISMA statement. Ann Intern Med. 2009;151:264-9.
38. Phillips B, Ball C, Sackett D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-Based Medicine Levels of Evidence. Version 2009. Available at: http://www.cebm.net/?o=1025.
39. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
40. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, et al. Rating quality of evidence and strength of recommendations: What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-8.
41. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336: 1106-10.
42. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al. Rating quality of evidence and strength of recommendations: incorporating considerations of resources use into grading recommendations. BMJ. 2008;336:1170-3.
43. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ. 2008;336:1049-51.
44. Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008; 337:a744.
45. Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory status convulsive epilepticus and recommendations for therapy. Brain. 2012;135:2314-28.